&w=3840&q=100)
Godrej Properties Q1 results: Net profit surges 15% to ₹598 crore
Press Trust of India New Delhi
Godrej Properties Ltd has reported a 15 per cent increase in its consolidated net profit to ₹598.40 crore for the first quarter of this fiscal.
Its net profit stood at ₹518.8 crore in the year-ago period.
Total income, however, fell to ₹1,620.34 crore in the April-June period of 2025-26 fiscal against ₹1,699.48 crore in the corresponding period of the preceding year, according to a regulatory filing on Friday.
During the 2025-26 fiscal, Mumbai-based Godrej Properties posted a net profit of ₹1,389.23 crore on a total income of ₹6,967.05 crore.
The company is one of the leading real estate developers in the country.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
7 minutes ago
- Hindustan Times
Godrej Properties on track to meet or exceed ₹32,500 cr pre-sales target for FY26: Pirojsha Godrej
New Delhi, Aug 3 (PTI) Godrej Properties is on track to meet or even exceed ₹32,500 crore sales bookings target for this fiscal as housing demand continues to be strong, its executive Chairperson Pirojsha Godrej said. Godrej Properties Executive Chairman Pirojsha Godrej said the exuberance seen in the housing market post-COVID has calmed down, but the demand condition is still pretty strong. (Mint File Photo ) In an interview with PTI, he noted that the exuberance seen in the housing market post-COVID has calmed down, but the demand condition is still pretty strong. In the first quarter of this fiscal, Godrej Properties Ltd reported an 18 per cent decline in its pre-sales or sales bookings to ₹7,082 crore. Pirojsha attributed the decline in pre-sales to high base effect and also a slight delay in launch of couple of projects. Nevertheless, he said, "We are very much on track to meet or exceed our booking value target for the current 2025-26 financial year". The company's launch pipeline for this fiscal is quite heavy, which will help in meeting the pre-sales target of ₹32,500 crore easily, said Pirojsha. Also Read: Godrej Properties acquires 34-acre land in Vadodara for plotted housing, marks second project in Gujarat Asked about the overall current housing market scenario considering global uncertainties, he said, 'I think definitely, the kind of very exuberant market that was there may be a year ago has definitely settled down a little bit. But this is exactly what we would expect to see.' In the first few years of upcycle, Pirojsha mentioned that there is always a huge pent-up demand and sharp price appreciations. "But I would say demand conditions still very strong, but not that kind of frothy looking demand that you see sometimes. So, I would say things have calmed down a little bit, but remain very, very positive," he observed. Many property consultants have reported a decline in the total housing sales across the top seven cities in the last two quarters. Pirojsha highlighted that the company's balance sheet is very strong, enabling it to make investments in land acquisition and development of projects for ensuring targeted growth of the overall business. Also Read: Godrej Air project: Home buyers protest delayed flats delivery During the last two financial years, Godrej Properties was the country's largest real estate firm in terms of sales bookings. The company is likely to retain its top rank for the third consecutive fiscal year if it achieves the sales bookings target of ₹32,500 crore. During the 2024-25 fiscal year, the company's sales booking rose 31 per cent to a record ₹29,444 crore from ₹22,527 crore in the preceding year. Also Read: Housing demand pretty strong across major cities but euphoria mellowing down: Pirojsha Godrej Q1FY25 results On the financial front, Godrej Properties recently reported a 15 per cent increase in its consolidated net profit to ₹598.40 crore for the first quarter of this fiscal as against ₹518.8 crore in the year-ago period. Total income, however, fell to ₹1,620.34 crore in the April-June period of 2025-26 fiscal against ₹1,699.48 crore in the corresponding period of the preceding year. Godrej Properties' sales booking or pre-sales declined 18 per cent to ₹7,082 crores during the April-June quarter from ₹8,637 crore in the year-ago period. The collection of funds from customers against bookings rose 22 per cent to ₹3,670 crore during the April-June quarter. Godrje Properties has a significant presence in Mumbai Metropolitan Region (MMR), Pune, Bengaluru, Delhi-NCR and Hyderabad where it is developing group housing projects. The company is doing residential plotted development projects in many tier II cities, like Indore and Panipat. The Mumbai-based firm posted a net profit of ₹1,389.23 crore on a total income of ₹6,967.05 crore during the last financial year.
&w=3840&q=100)
Business Standard
35 minutes ago
- Business Standard
Pharma Inc gears up for Day 1 launch of obesity drug in March 2026
As the global demand for next-generation diabetes and weight-loss therapies surge, Indian pharmaceutical companies are stepping up preparations to roll out generic versions of semaglutide—a blockbuster GLP-1 receptor agonist—once patent expires around March 2026. The generic launches will be significant, as the prices for the Indian consumer are expected to come down significantly from the current ₹17,000-26000 (monthly), thereby expanding the patient coverage. Dr. Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, and others are ramping up peptide manufacturing, forming device partnerships, and aligning regulatory strategies to capture a share of the global GLP-1 market, estimated to cross $150 billion by decade's end. Hyderabad-based DRL is planning Day 1 launches in India and Brazil, part of a 2026 global rollout across 87 countries. 'The semaglutide launch is very important to us,' said CEO Erez Israeli. The company aims to price its product below Novo Nordisk's current ₹17,000 monthly offering. DRL is also working on 26 GLP-1 therapies, backed by a ₹2,700 crore FY26 capex plan to scale peptide and biosimilar production. Cipla is targeting first-wave launches through a mix of in-house and partner filings. 'We see GLP-1 as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, MD and global CEO at the post earnings call. The company is building parts of its GLP-1 supply chain internally while leveraging partnerships to ensure scalability. Cipla is also crafting an affordable strategy for India's price-sensitive market, betting that post-patent price erosion will be offset by volume growth. Mankind Pharma aims to launch both oral and injectable semaglutide generics and is advancing MKP10241, a novel oral obesity drug in Phase 2 trials in Australia. Sun Pharma, meanwhile, is progressing its investigational GLP-1 molecule Utreglutide, targeted for launch in four to five years. It has secured Phase III approval for semaglutide trials in India, even as it reports negligible impact of GLP-1 drugs on its existing diabetes portfolio. The race for a piece of India's ₹628 crore anti-obesity market, however, comes at a time when the Indian courts and drug regulator body are looking to monitor the unregulated use of weight loss drugs. According to sources, the Central Drug Standards Control Organisation (CDSCO) has initiated work to form a panel after the Delhi High Court in July 2025 asked it to consult experts and relevant stakeholders to look into concerns arising out of approval for drug combinations being sold in the market for weight loss. The directive came in response to a public interest litigation filed by fitness entrepreneur Jitendra Chouksey, who had raised concerns about the marketing approval of drugs such as semaglutide, tirzepatide and liraglutide for weight management, despite limited safety data and the absence of India-specific clinical trials. While disposing of the petition, the court asked the drug regulator to respond to the petitioner within three months. At present, India has two officially available semaglutide brands: Rybelsus (oral) and Wegovy (injectable), both from Danish major Novo Nordisk. Rybelsus is approved for treating Type 2 diabetes, while Wegovy was launched in June 2025 for weight management. US-based Eli Lilly's tirzepatide drug, Mounjaro, is also available in India for obesity management. Analysts say the semaglutide opportunity is also fuelling India's peptide manufacturing ecosystem. 'Formulation is no longer enough—companies need full-stack execution,' said Nirali Shah, Pharma Analyst at Ashika Group, pointing to DRL, Cipla, and Sun Pharma's early moves to secure pen delivery partnerships. Contract development and manufacturing organisations (CDMOs) like Anthem Biosciences and Syngene are positioning themselves to capture a larger share of the growing peptide segment. Device manufacturers, too, are scaling up to meet rising demand for injection pens. India's peptide CDMO market, currently valued at $80 million, is growing at a CAGR of 14 per cent and could become a global supplier base for GLP-1 drugs, said Nilaya Varma, CEO of Primus Partners.
&w=3840&q=100)
Business Standard
35 minutes ago
- Business Standard
JAL insolvency: Jaiprakash Infratech to challenge bid rejection in court
Jaiprakash Infratech Ltd, the New Delhi-based real estate firm, is preparing to challenge in court the rejection of its bid to acquire Jaiprakash Associates Ltd (JAL), potentially dragging the bankrupt cement and infrastructure major's resolution into further delay. Lenders of JAL had turned down Jaiprakash Infratech's offer, citing an insufficient earnest money deposit (EMD), according to people familiar with the matter. The company had proposed a lien over fixed deposits in lieu of the ₹100 crore deposit, but the bid was rejected for not submitting the amount in the prescribed format and for delays in filing the offer. 'The lien over the fixed deposits was legally valid and submitted on time,' said a person close to the company, who asked not to be named as the discussions were private. 'We have no option but to move the court and remain in the race.' Jaiprakash Infratech, which was taken over by Mumbai-based Suraksha Group in June 2024, is currently focused on completing long-pending housing projects for customers who have waited over a decade. JAL, on the other hand, was sent for debt resolution after the company defaulted on loans worth ₹57,000 crore to Indian lenders. In March this year, the lenders transferred their outstanding dues to National Asset Reconstruction Company. The fresh legal dispute threatens to complicate the resolution process, with Gautam Adani's group emerging as the frontrunner to acquire the company after submitting an unconditional bid. Other suitors, including Dalmia Bharat, Vedanta Group, Jindal Power and PNC Infratech, have submitted offers with conditions attached. Lenders have now asked all bidders to submit revised proposals without conditions. Several of the conditional offers hinge on the fate of JAL's 1,000-hectare Sports City project in Greater Noida. In March, the Allahabad High Court upheld the cancellation of land allotment for the project by the Yamuna Expressway Industrial Development Authority. That decision is currently under appeal in the Supreme Court.
